We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Evaluation of the Resection Margins and the Ganglionic Status Using a Quality Standard Resection for Adenocarcinoma of the Head of the Pancreas (MRP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00918853
Recruitment Status : Completed
First Posted : June 11, 2009
Last Update Posted : March 20, 2015
Sponsor:
Information provided by (Responsible Party):
Institut Paoli-Calmettes

Brief Summary:
This multicentric prospective study evaluates the role of the margins resection and the ganglionic status when using a quality standard for the resection of adenocarcinoma of the head of the pancreas.

Condition or disease Intervention/treatment
Pancreas Adenocarcinoma Procedure: resection of adenocarcinoma of the head of the pancreas

Detailed Description:

Primary objective:

  • Evaluation of the prognosis role of the invasion of the margins on the overall survival after a standard resection of adenocarcinoma of the head of the pancreas.

Secondary objectives:

  • Evaluation of the prognosis role of the invasion:

    • Of margins on the overall survival.
    • Of each margins (distal pancreatic margin, gastric, posterior, retro-venous, retro-arterial) on the overall survival.
    • Of the ganglionic group of the superior mesenteric artery and the other nodes.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 156 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Evaluation of the Resection Margins and the Ganglionic Status Using a Quality Standard Resection for Adenocarcinoma of the Head of the Pancreas.
Study Start Date : August 2008
Primary Completion Date : May 2012
Study Completion Date : May 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: resection for adenocarcinoma
quality standard resection for adenocarcinoma of the head of the pancreas
Procedure: resection of adenocarcinoma of the head of the pancreas
quality standard for the resection of adenocarcinoma of the head of the pancreas



Primary Outcome Measures :
  1. Prognostic value of the invasion of the margins measured in millimetres on the overall survival [ Time Frame: 4 years ]

Secondary Outcome Measures :
  1. Relapse free survival: time between surgery and relapse or a right censure. The relapse is determined by clinical examination, biologic examination and imaging, which reveals metastasis or an isolated local relapse [ Time Frame: 4 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A head of the pancreas tumor compatible with adenocarcinoma diagnosis
  • tumor apparently removable
  • patient aged from 18 to older
  • signed consent

Non inclusion criteria:

  • pregnancy, breast feeding
  • patient in an urgency situation or patient with legal protection

Exclusion Criteria after surgery:

  • tumor other than adenocarcinoma of the head of the pancreas.
  • analysis of the margins not done with the defined criteria
  • nonadhesion to the surgical protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00918853


Locations
France
Chu D'Angers
Angers, France
Chu de Bordeaux
Bordeaux, France
Hopital Ambroise Pare
Boulogne, France
Chu de Clermont-Ferrand
Clermont-ferrand, France
Hopital Beaujon
Clichy, France
Hopital Henri Mondor
Creteil, France
Hopital de L'Antiquaille
Lyon, France
Hopital de La Croix-Rousse
Lyon, France
Hospices Civils de Lyon
Lyon, France
Chu La Conception
Marseille, France
Institut Paoli-Calmettes
Marseille, France
Centre Val D'Aurelle Paul Lamarque
Montpellier, France
Hotel Dieu
Nantes, France
Hopital Cochin
Paris, France
Hopital Pitie-Salpetriere
Paris, France
Hopital Tenon
Paris, France
Hopitial Saint Antoine
Paris, France
Hopital Pontchaillou
Rennes, France
Hopitaux Universitaires de Strasbourg
Strasbourg, France
Chu Purpan
Toulouse, France
Sponsors and Collaborators
Institut Paoli-Calmettes
Investigators
Principal Investigator: Jean Robert DELPERO, PhD Institut Paoli-Calmettes

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Institut Paoli-Calmettes
ClinicalTrials.gov Identifier: NCT00918853     History of Changes
Other Study ID Numbers: MRP/IPC 2007-005
ID-RCB 2007-A01326-47
First Posted: June 11, 2009    Key Record Dates
Last Update Posted: March 20, 2015
Last Verified: March 2013

Keywords provided by Institut Paoli-Calmettes:
pancreas
adenocarcinoma

Additional relevant MeSH terms:
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Pancrelipase
Pancreatin
Gastrointestinal Agents